A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
NCT00717457 on ClinicalTrials.gov · last registry update 2016-11-02
An unusually large phase 3: 1,189 participants, more than double the 424 typical for the stage. The sponsor logged completion for March 2011. Primary outcome, as filed: Change in HbA1c. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Enrollment
- 1,189
- Started
- 2008-07
- Primary completion
- 2011-03 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c
Conditions studied
Diabetes Mellitus Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.